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Abstract
Sudden hearing loss (SHL) is a common disease in the daily practice of ear-nose-throat 
(ENT) and audiology clinics. It is usually defined as a sensorineural type hearing loss 
of 30 dB or greater in three contiguous frequencies. Although several factors were sug-
gested for the etiology of SHL, in most of the cases, no cause could be detected and 
they were diagnosed as idiopathic cases. Although certain specific treatments might be 
applied in patients with known etiology, corticosteroids are the main component in the 
treatment of idiopathic SHL. Many experts and centers have developed different treat-
ment protocols with similar approaches. SHL is considered as an emergency in ENT, as it 
may cause a permanent loss in hair cells, if it is not treated or the treatment is not initiated 
at the right time. For patients, who did not or partially benefit from the initial treatment, 
different salvage treatment protocols had been developed. As SHL severely affects the 
patient’s quality of life, its diagnosis and treatment should be thoroughly deliberated.
Keywords: idiopathic hearing loss, salvage treatment, sudden deafness, sudden hearing 
loss, treatment
1. Definition
Sudden hearing loss (SHL) is an ear-nose-throat (ENT) emergency and as sensorineural hear-
ing loss of 30 dB or greater in three contiguous audiometric frequencies occurring over 72 h. 
SHL was first described by Dekleyn in [1] (Figure 1A). Although the definition mentioned 
above involves the widely accepted diagnostic criteria of SHL, it actually develops within 
hours or minutes and is usually noticed by the patient early in the morning or during a tele-
phone conversation. With an approach from a broader perspective, we may consider all iden-
tifiable and measurable hearing losses, which are noticed within minutes or within few days, 
as SHL. Patients usually visit an ENT specialist in a great panic, thinking they became deaf. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The physician, first of all, should calm the patient and then examine his/her medical condi-
tion, proceed immediately with the diagnostic procedures, identify—if possible—the etiology 
and initiate without delay the proper treatment.
2. Epidemiology
Although SHL constitutes approx. 1% of all sensorineural hearing losses, its incidence changes 
between 5 and 20/100,000 in different sources [2]. However, high rates such as 160/100,000 had 
also been reported in the literature and 40,000 new cases were diagnosed every year in the 
USA [3]. The incidence and prevalence of SHL are probably slightly higher than the calculated 
values, because of the rapid development of SHL and the high rate of spontaneous regression. 
Many studies reported that SHL had no correlation with gender and that the female/male 
ratio was equal or insignificantly different. In this regard, it seems safe to say that gender is 
not a risk factor. Similarly, no significant left/right ear distinction was detected. Although 
SHL is usually unilateral, bilateral involvement is emerging in a small percentage of patients 
(1–2%) [4]. Nevertheless, bilateral SHL is a more serious condition compared to the unilateral 
form and is often related to systemic disorders and has a relatively worse prognosis [5, 6].
3. Physiopathology
Among the mechanisms causing SHL, in particular, intracochlear hypoxia and/or inflamma-
tion in the inner ear play a major role. Several causes, which were suggested regarding the 
Figure 1. A: Sudden hearing loss sample audiogram. B: After treatment normal hearing level.
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pathogenesis of SHL, can be classified into four main groups. Vascular factors, viral infec-
tions, autoimmune processes, and intracochlear membrane rupture.
3.1. Vascular factors
As it is well known, the cochlea is an end-organ perfused by the labyrinthine artery, which is a 
branch of the basilar artery and does not have collateral circulation [7]. The labyrinthine artery 
divides into two branches (vestibular and cochlear arteries) after entering through the inter-
nal acoustic meatus. The cochlear artery enters the cochlea after the division of its branch the 
vestibulocochlear artery [8]. Therefore, factors such as thrombi, emboli, atherosclerosis, vaso-
spasm, and decreased blood flow may end up with vascular insufficiency and consequently 
a loss of function in the cochlea. A sudden interruption of the blood flow to the cochlea may 
induce the development of SHL, which will cause a complete restriction of the oxygen supply.
The obstructions in the vertebrobasilar system may also cause SHL. Here, it should be noticed 
that a bilateral SHL emerges, in these cases, as the basilar artery, which is the only artery sup-
plying that region. Kim et al. [9] detected a thrombus in the bilateral distal vertebral artery in 
a patient with bilateral SHL and observed improvement after the restoration of the circulation 
with a stent. In his experimental study, Perlman [10] stated that the occlusion of the internal 
auditory artery caused changes in the cochlea secondary to the ischemia and some of these 
changes were irreversible. The difference of this study from SHL patients is that the find-
ings in SHL are reversible. In a recent study similar to these studies, Chung [11] found out 
a relation between increased arterial stiffness and SHL development and the response to the 
treatment and drew attention to the development of SHL with vascular causes. Subclinical 
atherosclerosis has also been reported in the literature, as a cause of SHL [12].
It is understandable that the temporary and permanent problems in the cochlear microcircula-
tion may cause SHL depending on the damage in the cochlear hair cells [13]. Also, in cases of 
hypercoagulopathy, a possible intravascular obstruction may cause damage to the inner ear 
in the same way. Bernhard [14] investigated the effects of experimental hyperfibrinogenemia 
on the development of SHL and stated that although they did not respond to corticosteroids, 
intravenous defibrinogenation (ancrod) improved the process markedly. He suggested that 
defibrinogenation therapy should be considered in non-responding SHL patients. Similarly, 
the relation of SHL to the factors capable of intravenous obstruction such as sickle cell anemia, 
Waldenström’s macroglobulinemia or contraceptive drugs have been reported in the litera-
ture [15]. Although, some studies have suggested that there is a relationship between Factor 
V Leiden mutation and SHL, it was shown with a meta-analysis that there is no clear relation-
ship between these two pathologies [16]. It is clear that these diseases will not respond to 
corticosteroids and the main treatment should be targeted to the underlying cause. Cochlear 
damage may emerge due to the acute emboli after the cardiopulmonary bypass or non-oto-
logical, non-coronary operations and may result consequently in SHL [17]. Any obstruction 
due to any reason in the cochlear microcirculation will manifest itself with the symptoms cor-
responding to the level of the obstructed artery. For example, although hearing loss is the only 
finding in the presence of the cochlear artery obstructions, vestibular symptoms like vertigo 
and tinnitus will also emerge in the labyrinthine artery obstructions along with hearing loss.
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Cappacio [18] suggested that dyslipidemia may be associated with SHL pathogenesis and that 
impaired serum lipid profile might be an important factor in the development of SHL. There 
are also other studies in the literature linking serum lipid levels with SHL [19]. However, 
Chang [20] reported in his meta-analysis that serum lipid profile did not have any correlation 
with the SHL development and its prognosis.
3.2. Viral infections
Viral infections are the most common factor worldwide in the etiology of SHL in the world 
[21]. In 1954, Lindsay and Hemenway [22] detected degeneration in the tectorial membrane, 
corti organ, and stria vascularis during their cochlear histopathological examination and deter-
mined findings of measles virus in the cochlea in the same study. Shortly thereafter, Lindsay 
[23] found that the mumps virus could also do similar damage to the inner ear. So, the rela-
tionship between hearing loss and viral infections is well known. In a meta-analysis, it has 
been reported that 40% of the congenital hearing loss is associated with viruses and the most 
common responsible agent is cytomegalovirus (CMV) along with some other viral in utero 
infections [24]. Similarly, Van Dishoeck [25] suggested that there might be a link between 
upper airway infections and SHL and those upper airway viruses, which might penetrate the 
inner ear through neighborhood or blood circulation, might cause an immune response and 
an eventual damage in the inner ear. Especially, the herpes family of viruses, influenza, and 
enteroviruses are frequently blamed viral agents in the SHL etiology [26]. In a study conducted 
by Wilson [27], he found out that viral serology titration in SHL patients was two times higher 
than in the control group. It is believed that the penetration of the virus itself or the viral anti-
gens to the membranous labyrinth cause an immune response and the resulting inflammation 
the formation of SHL. As the emerged cochleitis causes hearing loss, it is believed that the 
presence of vertigo, which is considered as a sign of bad prognosis for SHL, depends on the 
labyrinthitis emerging concomitantly.
In addition to the viral infections, bacteria can also cause the formation of SHL. In the USA, 
the two most common bacterial diseases causing SHL are Lyme disease and syphilis [28]. 
Lyme disease is caused by Borrelia burgdorferi and in long-term it may involve neurologic 
structures, especially the seventh nerve, which may cause facial paralysis. It may also cause 
hearing loss due to the involvement of the eighth nerve [28]. Although some studies showed 
that the incidence of Lyme disease is relatively high in SHL (up to 20%), some other reported 
very low rates [29, 30]. Syphilis is a systemic infection caused by Treponema pallidum and may 
present diverse clinical manifestations. Especially at the stage of neurosyphilis, if the neuritis 
of eighth nerve and cochleitis are added to the picture, it is called as otosyphilis. Otosyphilis 
may be encountered in different forms such as SHL, progressive hearing loss, fluctuating 
hearing loss or Meniere’s syndrome [31].
In fact, viral infection hypothesis depends on three possible mechanisms considering its rela-
tion to the hearing loss [32]. The first of them, as mentioned above, is that the virus itself or 
its antigens, which may induce an immune response, penetrate the inner ear, and may cause 
cochleitis and neuritis in the cochlear nerve. The path may be hematogenous, but it may also 
spread directly through the neighborhood. The cerebrospinal fluid may be also a vehicle for 
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the spread of the virus. The second hypothesis is that the latent virus infection in the inner 
ear may reactivate due to several reasons and cause SHL. Especially, it is a fact that Varicella 
zoster and other neurotropic viruses may cause latent virus infections, which strengthens this 
hypothesis. The next hypothesis is more complicated than the first two hypotheses and is 
indirectly related to viruses as well. As follows: the antibodies found in the systemic circula-
tion and secreted against the viral antigens outside the inner ear may cause the development 
of a cross-reaction against the structural antigens in the inner ear, which may damage the 
inner ear and consequently cause hearing loss. In one respect, this last theory is an example of 
the relation between SHL and autoimmunity.
These findings, clinical, and histopathological studies eventually give the impression that 
viral etiology is one of the main etiologies in SHL. Nevertheless, it is also believed that the 
corticosteroids, which constitute the main therapeutic approach to SHL, have an anti-inflam-
matory effect in the inner ear, cures the emerged cochleitis, and enable healing through these 
mechanisms.
3.3. Autoimmunity
Autoimmunity theory is based on the main principle of the cross-reaction of the circulating 
antibodies or activated-cytotoxic T cells with the inner ear antigens [33]. The antibodies in the 
systemic circulation may be formed not only against a virus or bacterium, but also against 
several allergens. Eventually, these antibodies may become sensitive to the target antigens in 
the inner ear such as Type 2 collagen, tectorin, and beta-actin. The best documented among 
these antigens is the choline transporters like protein 2 (CTL-2) an inner ear glycoprotein [34–
38]. In a study, antibodies formed against CLK-2 were detected in the systemic circulation in 9 
of 20 patients [39]. In an experimental study on mice with Cogan syndrome, it was shown that 
the antibodies, which were formed against some supportive cells called CD148 and against 
connexin 26 (a well-known gap-junction protein), caused hearing loss [40].
In some SHL patients, antibodies against some cochlear proteins (p30, p80) and against some 
antigens such as Type 2 collagen and cardiolipin in the membranous labyrinth [41–43]. In 
some studies, it was also found out that the levels of some T-lymphocyte substances like C3b 
were increased in SHL [44]. Anti-endothelial antibodies (AECA) present another example. 
These antibodies are a group of heterogeneous autoantibodies that develop against endothe-
lial cells and cause damage to the vessel walls. These antibodies may cause inflammation in 
the vascular endothelial cells in many different regions of the body via the immune system. 
They were also associated with many connective tissue disorders and systemic vasculitis; 
therewith, they got specific terminological naming [45]. The relationship between AECA and 
SHL was demonstrated with several studies [46, 47]. Harris reported that the relationship 
between circulating antibodies and bilateral, progressive, and fluctuating SHL was suffi-
ciently evident [48]. In this study, although he detected antibodies against an antigen, which 
he thought was specific to the inner ear. He concluded that his further analyses revealed that 
this antigen was heat-shock protein 70 (Hsp-70) and that it existed not only in the inner ear, 
but also in different regions of the body. The relationship between the anti-Hsp70 antibodies 
and SHL were tried to be confirmed by further studies [49, 50].
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It has also been reported in the literature that there is a relation between systemic lupus ery-
thematosus (SLE) and SHL. It was reported that circulating autoantibodies might enter into 
the reaction directly with the inner ear antigens in SLE patients and the activated T cells might 
increase the levels of intracellular interferon gamma and some other cytokines and thus cause 
cellular damage [51]. Additionally, it is well known that in SLE, circulation antibodies such as 
anticardiolipin antibody, lupus anticoagulant, and anti-β2 GP1, antiphospholipid antibodies 
cause emboli and microinfarcts in the systemic circulation. As these antibodies may cause the 
same problems in the cochlear microcirculation, they may also cause SHL with the mecha-
nism explained in the vascular hypothesis of SHL. Meanwhile, it was also stated in the litera-
ture that the SHL, which is believed to be developed due to SLE, might improve with a proper 
anticoagulant treatment [52, 53].
Hearing losses, which are believed that they develop in relationship with autoimmunity 
and manifest themselves with progressive, recurrent, and fluctuating clinical picture, are 
also called autoimmune hearing loss or autoimmune inner ear disease [54]. Yoo [41] cre-
ated hearing loss in rats with Type 2 collagen immunization and showed the monoclonal 
antibodies, which were formed against the antigen related to the otic capsule, with radioim-
munoassay. Harris [55] identified five antibodies formed against the inner ear antigens and 
suggested that the inner ear might have its own immunoreactive mechanism apart from 
the systemic immune response, but this was not supported by studies conducted after this 
hypothesis was introduced. Lymphocyte transformation and Western-blot tests are recom-
mended for the diagnosis of the autoimmune hearing loss. Heywood [56] used infliximab 
in the treatment of fluctuating and progressive high-frequency recurrent hearing loss and 
reported that the patients benefited from this anti-TNF-alpha agent. Although all these find-
ings might show the place of the autoimmunity in the etiology of SHL, there is still a need 
for further studies with larger samples size, as the sample sizes in the available studies are 
relatively small.
3.4. Intracochlear membrane rupture
Round- and oval-window membranes are two anatomical structures that separate the inner 
and middle ear from each other. These structures are responsible for restricting the endo-
lymph to the inner ear and for preventing its penetration to the middle ear. There are other 
additional membranes in the inner ear that prevent the endolymph from interfering with 
the perilymph, and it is well known that their rupture will cause hearing loss. Goodhill [57] 
detected a perilymph fistula in three patients with SHL. Simmons [58] was one of the earli-
est authors, who suggested that the labyrinthine membrane damages might play a role in 
the etiology of SHL. Gussen [59] has identified healed Reissner membrane in the temporal 
bone dissections and succeeded to reveal membrane ruptures in the SHL etiology. Similarly, 
Kamerer [60] demonstrated microfissures between the posterior canal ampulla and the round-
window niche during his temporal bone studies. Although there are other studies with small 
patient sizes, the main question is whether the hearing losses depending on membrane rup-
tures should be classified as SHL. Because, in that case, we have to assume that SHL arises 
from a mechanical problem and the treatment procedure should be based mainly on surgical 
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or conservative procedures. But, the main thing that should be known about these patients is 
that they will not respond to standard SHL treatment protocols. However, if we look at the 
classic definition of SHL, they also conform to the SHL definition.
4. Histopathology
The histopathology of SHL is quite diverse because of the several factors blamed regarding 
its etiology. In the temporal bone studies, as mentioned above, along with the membrane rup-
tures, degenerative findings such as atrophy in the corti organ, loss of cochlear neurons, and 
neuron fibrils might be encountered in the viral etiology. On the other hand, histopathological 
findings such as labyrinthine fibrosis and new bone formation are the predominant histopath-
ological findings in vascular events. Yood [61] observed certain changes in 7 of 11 temporal 
bones in his histopathological study. These changes include especially damage to the corti 
organ or loss of total corti organ; even it may differ according to the etiology. On the other 
hand, Vasama [62] determined in his study on 12 temporal bones degeneration and loss in 
the spiral ligament and stria vascularis. He also observed cochlear ossification in one patient. 
Since SHL’s etiology is multifactorial, multiple histopathological findings are expected and it 
can be suggested that majority of these findings might be reversible regarding the spontane-
ous healing rates of SHL.
5. Etiology
Although an etiological factor could be determined only in a small number of SHL patients, 
a wide spectrum of etiologic factors and diseases were blamed. Among these, infectious 
cause being in the first place, vascular causes, endothelial dysfunctions, hyperlipidemia, 
hypercoagulopathy, increased oxidative stress, autoimmunity, trauma, neurological disor-
ders, endocrinopathies, iron deficiency anemia, neoplastic causes, paraneoplastic causes, 
and toxic causes are the most important factors. The most blamed causes in the SHL etiol-
ogy are shown in Table 1. But it should be emphasized that none of these factors has been 
confirmed as a cause of SHL and idiosyncrasy is still the most common category in SHL 
(Table 1).
Vascular Causes Trauma
Hypercoagulopathy Perilymph fistula
Vertebrobasilar Insufficiency Round window rupture
Thrombo-embolism Rupture of the oval window
Sickle Cell Anemia Intralabyrinthine hemorrhage
Moyamoya disease Temporal bone fractures
Polycythemia vera Previous otological surgeries
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Atherosclerotic disorders Previous cardiopulmonary surgeries
Arteriovenous malformations Acoustic trauma
Aneurysm
Erythrocyte Deformities Neoplastic Causes
Infection Acoustic Schwannoma
Viral Causes Multiple Myeloma
Herpes viridea family (HSV Type 1, 2; VZV, CMV, EBV) Metastatic tumors
Mumps Meningeal carcinomatosis
Rubella
Rubeola
HIV Endocrine Causes
Influenza family Hypothyroidism
Enteroviridea family Iron deficiency anemia
Adenovirus Diabetes mellitus
Human Spumaretrovirus Toxic Causes
Bacteria-Parasite Aminoglycosides
Treponema pallidum Gold
Borrelia burgdorferi Quinine
Toxoplasma gondii Iron-containing drugs
Mycoplasma spp. ACE inhibitors
Cryptococcus spp. Loop Diuretics
Meningococci Cisplatin
Enterobacteriae Aspirin
Autoimmune Causes Chemotherapeutic agents
Autoimmune inner ear disease Phosphodiesterase Type-5 inhibitors
Crohn’s Disease Heroin
Ulcerative Colitis Narcotic analgesics
SLE Benzodiazepines
Small vessel vasculitis Neurological Causes
Cogan syndrome Multiple Sclerosis
Antiphospholipid Antibody Syndrome Psychiatric Causes
Sarcoidosis Histrionic (somatoform) deafness
Endolymphatic hydrops İdiosyncrasy (most common cause)
Table 1. Etiology of sudden hearing loss.
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6. Medical history and physical examination
Medical history is typical in SHL. Patients usually notice in the morning, during a telephone 
conversation, after exiting a noisy environment that their hearing sense is suddenly disap-
peared and generally they visit panicked the nearest physician with a fear of being deaf. 
In sudden hearing loss, as patients consult immediately a physician, early diagnosis and 
treatment are possible. During the physical examination, as no SHL-specific finding can be 
detected during the bilateral otomicroscopic examination, otoscopic examination is usually 
normal. In some cases, there can be an obstructive ear plug, which may be removed with 
difficulty. At the same time, in patients with otological disorders like chronic otitis media 
and tympanic membrane retraction, previous audiometry reports might be needed for the 
diagnosis and especially in patients with presbyacusis and missing audiometry reports, diag-
nosing is relatively difficult. In such cases, we have to depend only on the anamnesis. In the 
anamnesis, the important points are the presence of tinnitus and ringing, the presence of 
concomitant vertigo, and presence of a similar event in the past. Questioning of these aspects 
will provide useful information regarding the differential diagnosis. The patients should also 
be evaluated for the known chronic diseases and used medication. Especially autoimmune 
disorders, coagulation disorders, cardiovascular diseases, previous infectious diseases, and 
trauma should be questioned. Following the physical examination, hearing examination 
(Weber, Rinne) should be carried out in order to evaluate the type and severity of the hearing 
loss. Afterwards, the diagnosis should be confirmed with pure-tone audiometry.
7. Diagnosis
7.1. Audiology
The audiological examination is the most important process regarding the diagnosis. Pure-
tone audiometry may enable a definitive diagnosis and also provide information about the 
severity of the hearing loss and the type of the audiological curve with additional data related 
to both differential diagnosis and prognosis. In addition to the pure-tone audiometry, tympa-
nometric examination, acoustic reflex, speech audiometry may support the diagnosis. Such 
additional tests are not always needed. They are only recommended if there is a clinical neces-
sity. In patients who cannot comply with the audiometry process ABR might be useful for the 
diagnosis. A definitive diagnosis of SHL can be made, if a hearing loss of 30 dB or greater is 
observed in three contiguous frequencies.
7.2. Laboratory analysis
As several different causes were suggested in respect of SHL etiology, the necessity of routine 
laboratory examination is still disputable regarding the diagnosis. The general consensus is 
that laboratory examination should be carried out only for the suspected etiological factors. 
If a viral involvement is suspected, viral antigen titration; if an autoimmune mechanism is 
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suspected, levels of the relevant auto-antibodies; thyroid function tests, homocysteine, PT, 
APTT, INR or markers like specific factor levels, Elisa for HIV, HCV viruses, fasting blood 
sugar level, HbA1C, lipid profile, VDRL, RPR for syphilis, Lyme titration, serum iron levels 
can be checked. The control of all these parameters in each patient is not reasonable and also 
not always possible so that it is much more appropriate to make these analyses only in sus-
pected etiological cases.
7.3. Radiology
In SHL, unlike the laboratory examinations, a radiological examination should be definitely 
performed considering the differential diagnosis. Approximately in 1% of patients diagnosed 
with SHL, a tumor was identified in the cerebellopontine angle. Therefore, a contrast-enhanced, 
thin-sectioned temporal MRI must be carried out regarding the differential diagnosis and 
to determine the etiological factor. In MRI examination, we may observe a space-occupying 
mass lesion and also in SHL cases with vascular pattern, we may also observe hyperinten-
sity in the pre-contrast examinations depending on the methemoglobin accumulated in the 
inner ear. In the presence of inflammation, hyperintensity might be observed in the 3D-flair 
sequence depending on the accumulation of the proteinous materials in the dense exudation 
[63]. Regarding the literature, the rate of the patients with MRI findings related to SHL was 
between 27 and 53% [64, 65]. In addition, MRI may also enable the identification of AICA 
aneurysms and vertebrobasilar system anomalies.
8. Treatment
As the etiological factor is mostly not identifiable in SHL, its treatment is arranged in certain 
protocols. Several therapeutic modalities clinically different but similar in respect of main 
aspects have been developed. Systemic corticosteroids are beyond dispute the main thera-
peutic agents and they are also considered as the golden standard in the literature. Moreover, 
multiple medical agents can be used in the treatment. In patients, who did not respond or par-
tially respond to the primary treatment, salvage treatment should be implemented. Although 
these treatments may change according to the patient and physician’s algorithm, it should be 
initiated with the primary treatment. In SHL cases with identified etiology, treatment should 
be targeted to the underlying disorder. Hereinafter, the treatment protocols especially for the 
idiopathic SHL will be discussed.
8.1. Medical treatment
8.1.1. Systemic corticosteroids
They are currently the main therapeutic agents (Figure 1B). They should be included in the treat-
ment protocols of SHL cases with unknown etiology. Although the mechanism of action of the 
corticosteroids considering the SHL pathogenesis is not fully elucidated, it is believed that they 
decrease the inflammation in the inner ear and accelerate the regeneration. An early initiation 
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of the systemic corticosteroid therapy enables a relatively better respond to the treatment [66]. 
Wilson [66], in his randomized double-blind placebo-controlled study, showed clearly the posi-
tive effect of the corticosteroids on the SHL. The following numerous studies confirmed these 
findings. Although there are few studies in the literature reporting that corticosteroids are inef-
fective, we observed in our clinical practice, that they are highly effective and included them 
in our routine treatment protocol. Systemic corticosteroid therapy is a short-term treatment, 
which is initiated with a dose of 1 mg/kg and continued with a gradual dose reduction. This 
treatment with gradually declining dosage enables that the suppressed adrenal glands have 
enough time to produce steroids again. The SHL treatment guideline, which was published by 
the American Otolaryngology Academia in 2012, indicated the corticosteroids as the first-line 
therapy. It was stated that a dose of 1 mg/kg for approx. 10–14 days is sufficient for the treatment 
of SHL [67]. Systemic corticosteroids have diverse side effects. The most common side effects 
are acne, blurred vision, cataract or glaucoma, sleeping problems, hypertension, increased appe-
tite, hypertrichosis, insomnia, immunosuppression, muscle weakness, irritability, uneasiness, 
osteoporosis, increase of insulin need in diabetic patients, diffuse edema due to the water and 
salt retention in kidneys, aseptic necrosis in the femur head. Steroids should be used carefully 
particularly in patients with comorbidity and in the pregnant and the risk-benefit of the therapy 
should be thoroughly evaluated. If in these patients corticosteroid use is risky, intratympanic 
corticosteroid injection should be considered in the primary treatment [68, 69].
8.1.2. Antiviral agents
Antiviral agents were added to the treatment protocols in many clinics in respect of the find-
ings related to the role of viruses in the etiology of SHL. Even though the responsible virus 
mostly cannot be isolated, they are used in combination with corticosteroids. Stookross cre-
ated labyrinthitis with HSV-1 antigens in an experimental animal study and applied cor-
ticosteroids as monotherapy or in combination with acyclovir. He observed that the viral 
replication was suppressed in the 14th day of the treatment and discontinued the application. 
He concluded that acyclovir and corticosteroid combination provided better recovery com-
pared to the corticosteroid monotherapy [70]. Park [71] conducted a study with 85 patients 
and administered a combination of steroid + antiviral + anticoagulant + stellar ganglion block-
age to one group and corticosteroid monotherapy to another group. He observed better recov-
ery in the combination group. In contrary, Westerlaken [72] conducted a placebo-controlled 
randomized study with 91 patients and administered acyclovir + corticosteroid combination 
in one group and corticosteroid alone in the other group. He concluded that antiviral agents 
did not provide additional benefit. Similarly, Tucci [73] concluded in his study conducted 
with 105 patients that the addition of valacyclovir to the corticosteroid therapy did not pro-
vide additional benefit and that antiviral treatment is ineffective in SHL. Antiviral agents like 
valacyclovir and famciclovir might be used instead acyclovir.
8.1.3. Vasodilators and plasma expanders
The goal of this treatment is to increase the blood perfusion in the inner ear and the oxygenation. 
In order to obtain this, either the arteries in the inner ear should be dilated or the viscosity 
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of the blood should be decreased in order to increase its fluidity. Papaverine, histamine, and 
carbogen (mixture of 5% CO
2
 and 95% O
2
) were used for this purpose in the literature. In 
particular, agents such as histamine and papaverine have found effective as they reduced sys-
temic vascular pressure [74]. Compared to these agents, carbogen treatment is more effective 
and provides a safer treatment option, which means that the oxygenation of the perilymph 
changes depending on the blood concentration of O
2
 and CO
2
 and systemic vascular resis-
tance. Especially, the partial CO
2
 level in the peripheral blood is an important stimulator of 
the perilymphatic oxygenation. Kallinen demonstrated that carbogen treatment increased the 
perilymphatic oxygenation more than 100% O
2
 [75]. There are plenty of studies conducted 
with piracetam, prostaglandin E1, dextran (plasma expander) and various rheological agents. 
These agents are not used alone in the idiopathic SHL but added to the systemic corticosteroid 
therapy protocol as adjuvant agents [76].
8.1.4. Diuretics
If endolymphatic hydrops is responsible for SHL, diuretics may be used in the treatment. 
Besides this, they are not included in the standard treatment protocols.
8.1.5. Magnesium
Nageris [77] showed that corticosteroid and magnesium combination is more effective in 
SHL compared to the corticosteroid and placebo combination. Similarly, Gordin [78] deter-
mined also that magnesium treatment had positive effects on the recovery in SHL via anti-
oxidant effects and recommended the addition of magnesium to the treatment regimes as an 
antioxidant.
8.1.6. Low-density lipoprotein apheresis
Low-density lipoproteins may cause the development of SHL, if their elevated concentrations 
increase the plasma viscosity. In a study with a large sample size, it was reported that the 
treatment with low-density lipoprotein apheresis and fibrinogen increased the recovery rate 
in SHL although the result was not statistically significant [79].
8.1.7. Ozone therapy
Ragab [92] conducted a study with 45 patients and reinjected the 100 ml blood, which he 
had taken from the patients and exposed to a 1:1 gas mixture of oxygen and ozone. After the 
implementation of this treatment protocol for a total of 10 sessions twice a week, he com-
pared the ozone group with the placebo group. He concluded that a significant recovery was 
observed in the ozone group.
8.2. Salvage therapies
If known treatment protocols provided no or limited response in SHL patients, salvage treat-
ments should be considered. The efficacy of the salvage treatments, which became popular 
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in the recent years, was shown in different studies with control groups. Hyperbaric O
2
 and 
intratympanic steroid treatment can be mentioned among these treatment principles.
8.2.1. Intratympanic steroid therapy (ITS)
We already mentioned that corticosteroids had a well-established efficacy in the treatment of 
SHL. In patients, in whom corticosteroids have limited use or efficacy, they may be adminis-
tered intratympanically with different methods. Thus corticosteroids penetrate through the 
middle ear membranes to the inner ear and achieve high concentrations, which consequently 
increased the recovery rate [80]. ITS is a treatment method, which has an ongoing increase in 
popularity, minimizes the side effects of corticosteroids and enables achievement of therapeu-
tic steroid concentrations with low doses. ITS is not only effective as a salvage therapy, but it 
also enables good results if it is combined with systemic corticosteroids during the primary 
treatment or administered as the primary treatment agent in patients, who cannot tolerate 
systemic steroids [81–84].
8.2.2. Hyperbaric oxygen therapy
Hyperbaric O
2
 therapy (HBO) is another salvage therapy method and investigated with a 
large number of studies. The basic principle is to increase the partial O
2
 pressure, which is 
decreased in the perilymph and cochlea in patients with SHL. Experimental studies have 
demonstrated that HBO increased the partial O
2
 pressure in the inner ear [85]. The increased 
partial O
2
 pressure in the inner ear supplies the needed O
2
 even if the blood flow is decreased 
and stimulates the cells. It decreases the platelet aggregation and increases the flexibility of 
the erythrocytes which positively affects the nutrition of the inner ear. Several recent studies 
demonstrated that the combined use of HBO therapy and corticosteroids or the use of HBO as 
a salvage therapy had positive effects on SHL [86–91]. The basic principle of the HBO therapy 
is to apply 100% O
2
 with a 2–3 atm pressure in repeated doses and to increase the O
2
 pressure 
in the inner ear with a controlled process. During the application of this procedure, the pos-
sible damage of the free O
2
 radicals should be taken into consideration.
8.3. Surgical treatment
Surgical treatment can only be carried out in a subgroup of patients with a known etiology. 
Cases with membrane ruptures, intracochlear membrane ruptures, endolymphatic hydrops, 
and acoustic neuroma can be treated with surgical interventions.
9. Prognosis
As SHL has a multifactorial etiology, the prognosis is variable. Considering all SHL cases, 
spontaneous regression rate is over 60%. In addition, some factors, which have positive or 
negative effects on the prognosis, have been described. Even though these factors do not 
change the treatment, they provide useful information about the course of the disease.
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The most important criterion is the time between the emergence of the symptoms and the 
initiation of the treatment. The prognosis is much better in patients started treatment early. 
Another factor is the age of the patient. An age less than 15 or greater than 65 years indi-
cates a bad prognosis. The prognosis worsens with the severity of the hearing loss. Although 
the prognosis is relatively better in the low-frequency hearing loss compared to the high-
frequency hearing loss, an ascendant type audiometric curve promises a better prognosis 
than the descendant type audiometric curve. The presence of vertigo and nystagmus, which 
shows that vestibular system is also affected, is a sign of bad prognosis. In contrary, tinnitus 
indicates a good prognosis in SHL, because tinnitus is considered as a sign that the hair cells 
in the inner ear are not completely destroyed. Bilateral SHL has a relatively worse progno-
sis. Increased sedimentation rate and an increase in the high sensitive CRP levels are related 
to the severity of the inflammation and thus to the bad prognosis. In SHL, recovery can be 
observed within 6 months to 1 year, it is wise to arrange the pre-rehabilitation follow-up plan 
according to this duration. In SHL patients, who did not show any recovery after 1 year, hear-
ing rehabilitation can be planned upon the patient’s request and according to the severity of 
the hearing loss.
10. Conclusion
As we have seen, SHL preserves its darkness as an enigma of ENT world. There are several 
already-published and a large number of ongoing studies on the etiology and treatment of 
SHL in the literature. Although certain diagnosis and treatment algorithms developed for 
SHL are already available, they cannot be implemented in all SHL cases. If corticosteroids 
cannot deliver sufficient results, there are not much treatment choices. Further studies for a 
full elucidation of the physiopathology, etiology, and treatment of SHL are required.
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